








Molecular Characterization of Infectious Laryngotracheitis Virus Circulating in Egypt during 2023

Nahed Yehia^{1*} , Sabry Omar² , Wessam Mady¹ , Zienab Mossad¹ , Dalia Said¹ , and Ahmed Abd Elhalem Mohamed¹ 

¹Reference Laboratory for Veterinary Quality Control on Poultry Production (RLQP), Animal Health Research Institute, Agriculture Research Center (ARC), Giza 12618, Egypt

²Poultry Diseases Department, Benha Provincial Laboratory, Animal Health Research Institute, Agriculture Research Center, Benha, Egypt

*Corresponding author's E-mail: NahedYehia@gmail.com

Received: April 06, 2025, Revised: May 10, 2025, Accepted: June 07, 2025, Published: June 30, 2025

ABSTRACT

Since its discovery in Egypt in 1983, the infectious laryngotracheitis virus (ILTV) has continued to spread, leading to substantial losses for poultry farms. This study aimed to identify and molecularly characterize the ILTV currently in circulation in Egypt in 2023. Fifteen pooled trachea and lung samples were collected from affected vaccinated and non-vaccinated layer farms (Shiver, Lohhman, Brown layer, and Aviagel) aged from 10-30 weeks old spread throughout eight governorates in Egypt. A real-time polymerase chain reaction (PCR) is used to detect ILTV. Ten positive samples representing various governorates were chosen for partial sequencing of the *ICP4* gene, and four positive samples were chosen for sequencing of the *TK*, *gD*, and *gG* genes. Using phylogenetic analysis, the *ICP4* clusters into chicken embryo origin vaccine and vaccine-like strains (CEO) and tissue culture origin vaccine and vaccine-like strains (TCO) and wild type. The GAHV-1-Egy-WO5-2023, GAHV-1-Egy-WO7-2023, and GAHV-1-Egy-WO8-2023 strains cluster in the CEO group with the CEO vaccine and vaccine-like strains with 98.9%–100% amino acid identity (A.A.); However, the remaining strains (GAHV-1-Egy-WO1-2023, GAHV-1-Egy-WO2-2023, GAHV-1-Egy-WO3-2023, GAHV-1-Egy-WO4-2023, GAHV-1-Egy-WO6-2023, GAHV-1-Egy-WO9-2023, and GAHV-1-Egy-WO10-2023) were clustered in the TCO group with TCO vaccine strains and vaccine-like strains with 100 % A.A. By analysis of *gD*, *gG*, and *Tk* genes, there is no difference between the TCO and CEO groups. Compared with several reference CEO and TCO vaccine strains and vaccine-like strains, some new specific mutations (Q161H and Q182H) were recorded in the *ICP4* in GAHV-1-Egy-WO8-2023. In addition, A34G, and P276L were recorded in the *gD* gene in the GAHV-1-Egy-WO1-2023 and GAHV-1-WO4-2023. Also, the R115I, G126A, and S163I were recorded in the *TK* gene in GAHV-1-Egy-WO8-2023 and A99E in GAHV-1-Egy-WO5-2023, which can affect the virulence and pathogenicity of the virus, which may be due to the reactivation of the vaccine strain by the bird-to-bird transmission or viral recombination. In conclusion, the ILTV outbreaks in poultry farms across several regions of Egypt during 2023 were induced by vaccine strains derived from TCO and CEO. Thus employing innovative vector vaccines and reassessing the current vaccination regimens is necessary.

Keywords: Infectious laryngotracheitis, Diagnosis, isolation, Genetic characterization

INTRODUCTION

Infectious laryngotracheitis virus (ILTV) is an acute respiratory disease affecting chickens all over the world and leading to significant economic losses (Bagust, 2003; Hong et al., 2024; Abebe et al., 2024; Shao et al., 2025). The ILTV is identified as Gallid herpesvirus 1 (GaHV-1) and belongs to the Herpesviridae family and subfamily of Alphaherpesvirinae (Elshafie et al., 2022). The ILTV

causes varying rates of morbidity and mortality of about 90% and 70%, respectively, as previously described by Bagust et al. (2000) and Coppo et al. (2013) based on the circulating strains' pathogenicity and whether they are co-infected with other respiratory pathogens (Menendez et al., 2014). The ILTV genome is 150-155 kilobases of linear double-stranded DNA that codes for inverted internal (IR)

and terminal (TR) repeats, unique long (UL), and unique short (US) repeats. UL and US sections encode 80 open reading frames (ORFs), whereas inverted repeats only contain three genes (*ICP4*, *US10*, and *sORF4/3*), as described by Lee et al. (2011) and Wu et al. (2022). The *ICP4* gene plays a crucial role in distinguishing distinct ILT strains (Creelan et al., 2006; Wang et al., 2021; Ponnusamy et al., 2022).

According to Lee (2011), ILTV encodes thymidine Kinase and 11 glycoproteins (*gL*, *gM*, *gH*, *gB*, *gC*, *gK*, *gG*, *gJ*, *gD*, *gI*, and *gE*) that are encoded by highly conserved ORFs. They have an essential role in the virulence and reproduction of viruses. The Glycoprotein G (*gG*) and the *TK* gene have been linked to ILTV pathogenicity (Han and Kim, 2001), and the *gD* protein functions as a virus-binding receptor to vulnerable cells (Di Giovine et al., 2011). Furthermore, the production of neutralizing antibodies is attributed to the glycoprotein B (*gB*) and glycoprotein D (*gD*) proteins (Rouse and Kaistha, 2006; Devlin et al., 2006; Lazear et al., 2012).

To prevent and control ILTV outbreaks, vaccines with modified live viruses are globally approved and utilized (Groves et al., 2019). Vaccine strains are propagated using either chicken embryos (CEO; chicken embryo origin) or cell culture (TCO; tissue culture origin). It has been seen that an attenuated virus vaccine can revert to virulence during bird-to-bird transmission (Groves et al., 2019; Kardoğan, Sarıçam, 2024). Numerous nations across the world, including the USA (Oldoni and García, 2007), Australia (Blacker et al., 2011), and Canada (Ojkic et al., 2006), have reported that modified live ILTV vaccinations, in particular CEO vaccines, are linked to illness outbreaks (Yi et al., 2024).

The most accurate and popular method for detecting ILTV infection is real-time PCR, which has good sensitivity, specificity, and speed (Davidson et al., 2015; Santander Parra et al., 2018; Asif et al., 2022). Viral isolation and serological assays can also identify an ILT virus infection. However, they are not very sensitive (Creelan et al., 2006; Zhao et al., 2013). Certain gene fragment sequencing appears helpful for defining field isolates and distinguishing vaccine strains from field isolates (Chacón and Ferreira, 2009; Shehata et al., 2013).

ILTV was first detected in Egypt in 1983 (Tantawy et al., 1983). Later, from 2011 to 2021, many field outbreaks were identified in various Egyptian governorates, leading to mortality rates and egg production declines of 20% to 35%, respectively. There was a noticeable sequence similarity between the detected viral strains and the vaccination strains utilized in Egypt. Some field isolates

were confirmed to be CEO-like viruses (Shehata et al., 2013), and some detected both TCO-like and CEO-like viruses (Bayoumi et al., 2020; Mossad et al., 2022), and they can result in the creation of natural recombinants with each other (Lee et al., 2012). In field outbreaks, field and ILTV vaccination strains are hard to differentiate (Lee et al., 2012). Therefore, molecularly defining the circulating ILTV strains in affected poultry farms is essential.

Several molecular characterization methods are employed to differentiate the strains causing outbreaks. PCR followed by restriction fragment length polymorphism (PCR-RFLP) was used to effectively distinguish field and vaccine strains (Chang et al., 1997; Kirkpatrick et al., 2006; Hermann et al., 2024). However, this technique's applicability is limited by the substantial amount of DNA required (Chacón and Ferreira, 2009). Specific gene fragment sequencing appears to be useful for differentiating vaccine strains from field isolates and characterizing field isolates.

The present study aimed to detect, identify, and characterize four antigenic and functionally relevant genes (*ICP4*, *gD*, *gG*, and *TK*) of the ILT virus strains currently circulating in Egypt in 2023.

MATERIAL AND METHODS

Ethical approval

The study was conducted according to the Animal Health Research Institute guidelines of Benha Provincial Laboratory, Animal Health Research Institute, Agriculture Research Center, Benha, Egypt.

Sample collection

During 2023, the tracheal, larynx, and lung field samples were collected from 50 freshly dead affected layer farms (Shiver, Lohhman, Brown layer, and Aviagel) aged from 10-30 weeks with average sizes (10000-15000) birds. The samples included 37 unvaccinated layer chicken farms and 13 vaccinated layer chicken farms. They were vaccinated with TCO (LT-IVAX, USA) and CEO (Nobilis® ILT, Netherlands), administered at 35 and 95 days of age, respectively. The samples were collected from eight Governorates in Egypt, including eight from El Sharkia, ten from Qalubia, fifteen from Dakahlia, seven from Monofia, three from Gharbia, two from Behira, two from Damietta, and three from Alexandria.

The affected chickens experienced severe respiratory symptoms, such as coughing, sneezing, gasping, expectoration of red exudates from respiratory orifices, difficulty in inspiration, infra-orbital sinus enlargement,

and significant mortality (5-15% mortality). Upon post-mortem inspection, the field instances had congested and hemorrhagic tracheitis with blood clots and caseated material, and in a few cases, this led to a blocked laryngeal lumen. The 10 trachea, larynx, and lungs from each farm were homogenized in sterile phosphate buffer saline PBS and then centrifuged at 3000 rpm at 4°C for 30 minutes to clarify them.

Screening and detection of infectious laryngotracheitis virus by real-time PCR

DNA was extracted from the supernatant fluid using the QIAamp DNA Mini kit (QIAGEN, Hilden, Germany) in accordance with the manufacturer's instructions. In conclusion, 10 µl of proteinase K, 200 µl of lysis buffer, and 200 µl of sample solution were incubated at 56 °C for 10 minutes, then 200 µl of 100% ethanol was added. 50 µl of elution buffer was used to elute DNA from the lysate. Real-time PCR used specific primers and probes targeting the *gB* gene (Table 1). Using the Takara kit (Kusatsu, Japan) according to the manufacturer's instructions through the Stratagene Mx3005p Real-Time PCR System.

Virus isolation

Three specific pathogen-free (SPF) chicken eggs, ranging in age from ten to twelve days, and 0.2 ml of positive samples were inoculated in the chorioallantoic membrane (CAM). The inoculated eggs were incubated at 37°C for a maximum of seven days with daily monitoring and investigation of the presence of distinctive pock lesions on the CAMs of dead embryos or even survival eggs in 7 days (Magouz et al., 2018; Wolfrum et al., 2020).

Genetic characterization of *ICP4*, *gD*, *gG*, and *TK* genes

Conventional PCR amplification

Using gene-specific primers, the *ICP4*, *gD*, *gG*, and *TK* genes of the isolated ILTV were partially amplified by PCR (Table 2). The PCR was carried out in an ABI thermocycler (ProFlex™ PCR System) using the EmeraldAmp GT PCR MasterMix from Takara, Kusatsu, Japan. Certain PCR products were electrophoresed on a 1.5% agarose gel, stained with ethidium bromide, and examined under an ultraviolet lamp. Their purification procedure used the QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany).

Table 1. Real-time primers and probes used for the detection of infectious laryngotracheitis virus

Primers and probe	Sequence	Reference
<i>gB</i> -S	5' CAGTATCTGGCATCGCCTCAT '3	(Zhao et al., 2013)
<i>gB</i> -A	5' CCTGGGAACAGAACCTGAACT '3	
Probe	5' FAM-CTAACCCGTTTCGCCGCACTCG-BHQ-1 '3	

Table 2. Primers used for amplification of *ICP4*, *TK*, *gD*, *gG* genes

Primer	Sequence	Weight (BP)	Reference
<i>ICP4</i> -1F	5'ACTGATAGCTTTTCGTACCAGCACG'3	688	(Chacón and Ferreira, 2009)
<i>ICP4</i> -1R	5'CATCGGGACATTCTCCAGGTAGCA'3		
<i>TK1b</i> -F	5'CTTAGCGGAACCTATGCAAG'3	781	The present study
<i>TK</i> -R	5'GAG GCC ATG TGC TGG TAA GT'3		
<i>gD</i> -F	5'ATG CAC CGT CCT CATC'3	1300	(Craig et al., 2017)
<i>gD</i> -R	5'TTA GCT ACG CGC GCAT'3		
<i>gG</i> -F	5'CCT TCT CGT GCC GAT TCA ATATG'3	1480	(Craig et al., 2017)
<i>gG</i> -R	5'AAC CAC ACC TGA TGC TTT TGTAC'3		

Gene sequencing and phylogenetic analysis

Using the Big Dye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, California, USA) and ABI 3500XL Genetic Analyzer (Life Technologies, California, USA) with gene-specific primers, amplicons of ten positive samples representing different governorates and vaccinated and unvaccinated flocks (Table 3) were partially sequenced for *ICP4*. Four of the ten isolates were chosen to be partially sequenced for the *gD*, *Gg*, and *TK* genes. The sequence was posted to the GenBank (NCBI) website using the accession number (Table 4). Nucleotide and amino acid sequences of sequenced samples against

further strains of ILTV from different groups and vaccine strains obtained from the National Center for Biotechnology Information (NCBI) (Table 5) were aligned using DNASTAR software's MegAlign module and CLUSTAL-W tool (Lasergene version 7.2; DNASTAR, Madison, WI, USA, Burland, 2000). MEGA version 6 generated the phylogenetic tree using 1000 bootstrap repeats and a moderate-strength maximum likelihood approach (Tamura et al., 2013; Kumar et al., 2016). The pairwise amino acid identity percent was calculated using the DNASTAR software (DNASTAR, Madison, WI, Burland, 2000).

Table 3. The epidemiological data of sequenced isolates of the Infectious Laryngotracheitis virus

Name	Governorates	Breed	Age (day)	Mortality percent (%)	Vaccination
ILT-Egy-WO1-2023	El Sharkia	Shiver	70	5%	Non vaccinated
ILT-Egy-WO2-2023	Dakahlia	Lohhman	100	10%	Non vaccinated
ILT-Egy-WO3-2023	Behira	Brown layer	120	7%	Vaccinated
ILT-Egy-WO4-2023	Monofia	Aviagel	150	8%	Vaccinated
ILT-Egy-WO5-2023	Dakahlia	Lohhman	160	9%	Vaccinated
ILT-Egy-WO6-2023	Qalubia	Shiver	80	12%	Non vaccinated
ILT-Egy-WO7-2023	Gharbia	Lohhman	100	6%	Vaccinated
ILT-Egy-WO8-2023	Monofia	Aviagel	90	11%	Non vaccinated
ILT-Egy-WO9-2023	Domiat	Lohamn	110	13%	Non vaccinated
ILT-Egy-WO10-2023	Qalubia	Aviagel	180	14%	Non vaccinated

TCO (LT-IVAX, USA) and CEO (Nobilis® ILT, Netherlands) vaccines were administered to the chickens at 35 and 95 days of age in vaccinated flocks.

Table 4. Accession number of sequenced strains of Infectious Laryngotracheitis virus

Name	Accession number	ICP4	gG	gD	TK
ILT-Egy-WO1-2023		OR900664	OR900656	OR900649	OR900660
ILT-Egy-WO2-2023		OR900665	-	-	-
ILT-Egy-WO3-2023		OR900666	-	-	-
ILT-Egy-WO4-2023		OR900667	OR900657	OR900650	OR900662
ILT-Egy-WO5-2023		OR900668	OR900658	OR900651	OR900661
ILT-Egy-WO6-2023		OR900669	-	-	-
ILT-Egy-WO7-2023		OR900670	-	-	-
ILT-Egy-WO8-2023		OR900671	OR900659	OR900652	OR900663
ILT-Egy-WO9-2023		OR900672	-	-	-
ILT-Egy-WO10-2023		OR900673	-	-	-

Table 5. Reference strains provided by the National Center for Biotechnology Information (NCBI)

Name	Country	Virulent/ Vaccine	Accession Number
GAHV1-SA2	Australia	Vaccine	JN596962
GAHV1-TCO-IVAX	USA	Vaccine	JN580312
GAHV1-CEO-TRVAX	USA	Vaccine	JN580313
GAHV1-81658	USA	Virulent	JN542535
GAHV1-USDA-REF	USA	Virulent	JN542534
GAHV1-LTI-IVAX	USA	Vaccine	FJ444832.1
GAHV1-TCO-low passage	USA	Vaccine	JN580315
GAHV1-TCO-high passage	USA	Vaccine	JN580314
GAHV1-TCO vaccine	USA	Vaccine	EU104908.1
GAHV1-40798	Korea	Virulent	MH937566.1
GAHV1-ACC78	Australia	Virulent	JN804826
GAHV1-CEO-high passage	USA	Vaccine	JN580316
GAHV1-V1-99	Australia	Virulent	JX646898
GAHV1-K317	China	Virulent	JX458824
GAHV1-Live attenuated serva (Nobilis)	Australia	Vaccine	HQ630064
GAHV1-CEO-low passage	USA	Vaccine	JN580317
GAHV1-Intervet	Italy	Vaccine	HM230782.1
GAHV1-LT-BLEN	USA	Vaccine	JQ083493
GAHV1-CL9	Australia	Virulent	JN804827
GAHV1-63140	USA	Virulent	JN542536
GAHV1-CEO Vaccine	USA	Vaccine	EU104900.1
GAHV1-Laryngo Vac	USA	Vaccine	JQ083494.2
GAHV1-Poultvac	Italy	Vaccine	KP677882.1

RESULTS

Clinical signs and post-mortem examination

The chicken had red exudates from respiratory orifices, sneezing, coughing, gasping, nasal and ocular discharges, difficulty inhaling, and swelling of the infra-orbital sinus, with a mortality rate of 5-15% (Figure 1).




Figure 1. Clinical signs and post-mortem lesions were caused by the infectious laryngitis virus in affected chickens. **A:** gasping and respiratory signs in affected chickens. **B:** The trachea had Fibrinohemorrhagic exudate linked to hemorrhage and congestion in the lumen.


Post-mortem examination of the trachea and larynx indicated hemorrhage and congestion of the mucosa, along with a cast of fibrin-hemorrhagic blood obstructing the lumens. Caseous material was also discovered in the trachea and larynx. The lungs showed areas of congestion and consolidation (Figure 1).

Infectious Laryngitis virus screening by real-time PCR and viral isolation

Real-time PCR for 40 of the 50 samples was positive (5/8 El Sharkia, 8/10 Qalubia, 14/15 Dakahlia, 6/7 Monofia, 2/3 Gharbia, 2/2 Behira, 2/2 Domiatt, and 1/3 Alexandria) (Figure 2). The isolated positive samples on SPF-ECE indicated opaque, raised border pockets-like lesions distinguished by a grey core zone of necrosis and hemorrhagic chorioallantoic membrane. After inoculation, most embryos die 2-7 days later, and they are accompanied by slow development.

Gene amplification by conventional PCR

Ten isolates out of forty positive samples were selected according to different governorates to be amplified by conventional PCR for further sequencing for *ICP4* at 688 bp (Figure 3). Four isolates were partially amplified for *gD*, *gG*, and *TK*, genes sequencing at the expected weights 1300, 1480 and 781 bp, respectively.






Figure 2. The colored amplification curves of the positive and negative controls, and 40 positive samples, in addition to the curve of 10 negative samples of the infectious laryngitis virus in affected chickens in Egypt (A and B)




Figure 3. *ICP4* Genes amplification 10 positive samples by conventional PCR of the infectious laryngitis virus in affected chickens in Egypt.

Genetic characterization and phylogenetic analysis

Ten isolates were partially sequenced for the *ICP4* gene, while 4 isolates were selected for *gD*, *gG*, and *TK* partial sequencing. To detect similarity levels and analyze gene mutations, a multiple sequence alignment was created using sequenced strains in this study, other strains circulating in Egypt, strains from other countries, chicken embryo vaccine, and tissue culture origin vaccine (Table

5). The ILTV strains were clustered into two categories based on *ICP4* partial sequence-based phylogenetic analyses, including tissue culture origin (TCO) vaccines and vaccine-like strains, and chicken embryo origin (CEO) vaccines and vaccine-like strains. The third group (Wild type), including field isolates from Brazil and the United States, was identified (Figure 4).

The phylogenetic tree of *ICP4* gene (Figure 4) revealed that 7 of Egyptian strains under study (GAHV-1-Egy-WO1-2023, GAHV-1-Egy-WO2-2023, GAHV-1-Egy-WO3-2023, GAHV-1-Egy-WO4-2023, GAHV-1-Egy-WO6-2023, GAHV-1-Egy-WO9-2023 and GAHV-1-Egy-WO10-2023) belonged to the TCO group together with TCO vaccine strains (TCO low passage, TCO high passage, IVAX that used in Egypt) and virulent vaccine like strains from USA (USDA, 81658) and Egyptian strains from 2015-2021 (Giza-2, Kaliobia-5, CLEVB-222, CLEVB-221). The remaining three strains in this study (GAHV-1-Egy-WO5-2023, GAHV-1-Egy-WO7-2023, and GAHV-1-Egy-WO8-2023) belong to the CEO group, along with virulent vaccine like strains from Australia (ACC78) and CEO vaccine strains (CEO low passage, CEO high passage, LT Blen, TRVX, and live attenuated serva vaccine that is used in Egypt).

The phylogenetic analysis of the *gD* and *gG* genes (Figures 5, 6) revealed no difference between the TCO and CEO strains. All strains in this study cluster with the TCO vaccine strains (IVAX), CEO vaccine strains (live attenuated serva, LT Blen, TRVX), and USDA, 81658, ACC78 virulent vaccine-like strains from the USA, Australia, as well as several Egyptian strains (Mansura-2019, Sharkia-2018). However, in the phylogenetic tree of the *gD* gene, the GAHV-1-Egy-WO1-2023 and GAHV-1-Egy-WO4-2023 were clustered on a separate branch with Fayoum_2019 and Qalubia_2018.

The thymidine kinase phylogenetic study shows no differences between TCO and CEO strains. All strains in this study were clustered with the TCO vaccine strain (IVAX), CEO vaccine strains (LT Blen, TRVX, live attenuated serva), various Egyptian strains (Sharkia11, Egypt-2015), and virulent vaccine like strains from the USA (USDA, 81658,) and Australia (ACC78) (Figure 7).

The *ICP4* gene of seven strains (GAHV-1-Egy-WO1, GAHV-1-Egy-WO2, GAHV-1-Egy-WO3, GAHV-1-Egy-WO4, GAHV-1-Egy-WO6, ILT-Egy-WO9 and ILT-Egy-WO10) had 100% amino acid identity percent with TCO vaccine strains (IVAX that used in Egypt), virulent vaccine like strains from USA (USDA, 81658) and Egyptian strains (Giza-2, Kaliobia-5, CLEVB-222, CLEVB-221). The other three isolates (GAHV-1-Egy-WO5, GAHV-1-Egy-WO7, and GAHV-1-Egy-WO8) had 98.9%-100% with CEO vaccine strains (live attenuated serva, that were used in Egypt, LT Blen, TRVX) and virulent vaccine like strains from Australia (ACC78) and 96.7%-97.8% with Egyptian strains (Monofia-1-2021 and Kaibia-3-2021; Figure 8).

The *gD* gene of four strains (GAHV-1-Egy-WO1-2023, GAHV-1-Egy-WO4-2023, GAHV-1-Egy-WO5-2023 and GAHV-1-Egy-WO8-2023) had 99.8%-100% A.A. identity percent with -TCO vaccine (IVAX that used in Egypt) and CEO vaccine strains (LT Blen, TRVX, live attenuated serva that used in Egypt) and other virulent vaccine like strains from Australia (USDA, 81658, ACC78). While GAHV-1-Egy-WO5-2023 and GAHV-1-

Egy-WO8-2023 had 99.8%-100% relation to many Egyptian strains (Alexandria-2018, Sharkia-2018, Mansura 2019, and Fayum-2019), GAHV-1-Egy-WO1-2023 and GAHV-1-Egy-WO4-2023 had 99.7-99.8% relation (Figure 9).

The *gG* gene of all sequenced strains had 100% A.A. identity percent with TCO vaccine strains (USDA, IVAX used in Egypt), CEO vaccine strains (LT Blen, TRVX, live attenuated serva used in Egypt), virulent vaccine like strains from the USA (81658) and Australia (ACC78) and several Egyptian isolates (Sharkia-2018; Mansura- 2019; Fayum-2019; Figure 10).

The *Tk* gene of GAHV-1-Egy-WO1-2023 and GAHV-1-Egy-WO4-2023 had 100% A.A. identity percent with TCO vaccine strain (IVAX that used in Egypt), CEO vaccine strains (LT Blen, TRVX, live attenuated serva), virulent vaccine like strains from USA (USDA, 18685) and Australia (ACC78) and other Egyptian strains (Sharkia-11, Egypt-2015) but GAHV-1-Egy-WO5-2023 and GAHV-1-Egy-WO8-2023 had 97.2%-99.1% A.A. identity with TCO vaccine strain (IVAX that used in Egypt), CEO vaccine strains (LT Blen, TRVX, live attenuated serva), virulent vaccine like strains from USA (USDA, 18685) and Australia (ACC78) and other Egyptian strains (Sharkia-11, Egypt-2015; Figure 11).

Mutation analysis

Comparing several reference CEO and TCO vaccine strains, and virulent vaccine-like strains from the USA, Australia, China, and Egypt between 2015 and 2021, listed in GenBank (Table 5). No mutations were detected in the *ICP4* in the seven strains related to TCO in this study (GAHV-1-Egy-WO1-2023, GAHV-1-Egy-WO2-2023, GAHV-1-Egy-WO3-2023, GAHV-1-Egy-WO4-2023, GAHV-1-Egy-WO6-2023, GAHV-1-Egy-WO9-2023, and GAHV-1-Egy-WO10-2023). All strain-related to CEO related strains in these studies (GAHV-1-Egy-WO5-2023, GAHV-1-Egy-WO7-2023, and GAHV-1-Egy-WO8-2023) had a deletion at 272 to 283 pb and V200M that is characteristic of the CEO vaccine and CEO vaccine-like strain. Also, the GAHV-1-Egy-WO8-2023 had Q161H and Q182H.

The *Gd* genes of GAHV-1-Egy-WO5-2023 and GAHV-1-Egy-WO8-2023 did not have any mutations, and GAHV-1-Egy-WO1-2023 and GAHV-1-Egy-WO4-2023 had A34G and P276L. No mutations were detected in the *Gg* gene in all sequenced strains in this study, and it had threonine at positions 67 and 103 was unique to the vaccination strain. The *TK* genes of GAHV-1-Egy-WO1-2023 and GAHV-1-Egy-WO4-2023 had no mutations; however, GAHV-1-Egy-WO5-2023 had A99E, and GAHV-1-Egy-WO8-2023 had R115I, G126A, and S163I.




Figure 4. The phylogenetic analysis of the *ICP4* gene of the study strain in comparison to several field and vaccination strains of infectious laryngitis virus (ILTV) using the MEGA 6.0 program's maximum likelihood technique. The strains in this study are indicated by black dots.




Figure 5. The phylogenetic analysis of the *gD* gene of the study strain in comparison to several field and vaccination strains of infectious laryngitis virus (ILT) using the MEGA 6.0 program's maximum likelihood technique. The strains in this study are indicated by black dots.




Figure 6. The phylogenetic analysis of the *gG* gene of the study strain in comparison to several field and vaccination strains of infectious laryngitis virus (ILTV) using the MEGA 6.0 program's maximum likelihood technique. The strains in the current study are indicated by black dots.




Figure 7. The phylogenetic tree of the *TK* gene of the study strain compared to several field and vaccination strains of infectious laryngitis virus (ILTV) using the MEGA 6.0 program's maximum likelihood technique. The strains in this study are indicated by black dots.

		Percent Identity																														
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27					
Divergence	1	█	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	97.2	97.2	70.0	97.2	97.2	97.2	97.2	97.2	99.4	99.4	96.1	97.2	97.2	1	GaHV-1-TCO-vaccine		
	2	0.0	█	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	97.2	97.2	70.0	97.2	97.2	97.2	97.2	97.2	99.4	99.4	96.1	97.2	97.2	2	GaHV-1-TCO-IVAX		
	3	0.0	0.0	█	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	97.2	97.2	70.0	97.2	97.2	97.2	97.2	99.4	99.4	96.1	97.2	97.2	3	GaHV-1-81658		
	4	0.0	0.0	0.0	█	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	97.2	97.2	70.0	97.2	97.2	97.2	97.2	99.4	99.4	96.1	97.2	97.2	4	GaHV-1-USDA-reference		
	5	0.0	0.0	0.0	0.0	█	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	97.2	97.2	70.0	97.2	97.2	97.2	97.2	99.4	99.4	96.1	97.2	97.2	5	GaHV-1-ILT-Egy-GIZA2-2021		
	6	0.0	0.0	0.0	0.0	0.0	█	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	97.2	97.2	70.0	97.2	97.2	97.2	97.2	99.4	99.4	96.1	97.2	97.2	6	GaHV-1-ILT-Egy-kaliobia5-2021		
	7	0.0	0.0	0.0	0.0	0.0	0.0	█	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	97.2	97.2	70.0	97.2	97.2	97.2	97.2	99.4	99.4	96.1	97.2	97.2	7	GaHV-1-ILT-Egy-CLEVB-222-2016		
	8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	█	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	97.2	97.2	70.0	97.2	97.2	97.2	97.2	99.4	99.4	96.1	97.2	97.2	8	GaHV-1-ILT-Egy-CLEVB-221-2016	
	9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	█	100.0	100.0	100.0	100.0	100.0	100.0	97.2	97.2	70.0	97.2	97.2	97.2	97.2	99.4	99.4	96.1	97.2	97.2	9	GaHV-1-Egy-WO1-2023		
	10	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	█	100.0	100.0	100.0	100.0	100.0	97.2	97.2	70.0	97.2	97.2	97.2	97.2	99.4	99.4	96.1	97.2	97.2	10	GaHV-1-Egy-WO2-2023		
	11	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	█	100.0	100.0	100.0	100.0	97.2	97.2	70.0	97.2	97.2	97.2	97.2	99.4	99.4	96.1	97.2	97.2	11	GaHV-1-ILT-Egy-WO3-2023		
	12	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	█	100.0	100.0	100.0	97.2	97.2	70.0	97.2	97.2	97.2	97.2	99.4	99.4	96.1	97.2	97.2	12	GaHV-1-Egy-WO4-2023		
	13	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	█	100.0	100.0	97.2	97.2	70.0	97.2	97.2	97.2	97.2	99.4	99.4	96.1	97.2	97.2	13	GaHV-1-Egy-WO6-2023		
	14	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	█	100.0	97.2	70.0	97.2	97.2	97.2	97.2	99.4	99.4	96.1	97.2	97.2	14	GaHV-1-Egy-WO9-2023		
	15	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	█	97.2	97.2	70.0	97.2	97.2	97.2	97.2	99.4	99.4	96.1	97.2	97.2	15	GaHV-1-Egy-W10-2023	
	16	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	█	100.0	72.8	100.0	100.0	100.0	100.0	97.8	97.8	98.9	100.0	100.0	16	GaHV-1-CEO-vaccine	
	17	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	█	72.8	100.0	100.0	100.0	100.0	97.8	97.8	98.9	100.0	100.0	17	GaHV-1-CEO-TR/VX
	18	35.1	35.1	35.1	35.1	35.1	35.1	35.1	35.1	35.1	35.1	35.1	35.1	35.1	35.1	35.1	34.2	34.2	█	72.8	72.8	72.8	72.8	70.6	70.6	71.7	72.8	72.8	18	GaHV-1-Laryngo-Vac		
	19	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.0	0.0	34.2	█	100.0	100.0	100.0	97.8	97.8	98.9	100.0	100.0	19	GaHV-1-live-attenuated-Serva		
	20	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.0	0.0	34.2	0.0	█	100.0	100.0	97.8	97.8	98.9	100.0	100.0	20	GaHV-1-LT-Blén		
	21	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.0	0.0	34.2	0.0	0.0	█	100.0	97.8	97.8	98.9	100.0	100.0	21	GaHV-1-ACC78		
	22	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.0	0.0	34.2	0.0	0.0	0.0	█	97.8	97.8	98.9	100.0	100.0	22	GaHV-1-K317		
	23	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.0	0.0	34.2	0.0	0.0	0.0	0.0	█	100.0	96.7	97.8	97.8	23	GAHV-1-ILT-Egy-MONOFIA1-2021		
	24	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.0	0.0	34.2	0.0	0.0	0.0	0.0	0.0	█	96.7	97.8	97.8	24	GAHV-1-ILT-Egy-kaliobia3-2021		
	25	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.1	1.1	36.0	1.1	1.1	1.1	1.1	1.1	1.1	█	98.9	98.9	25	GaHV-1-Egy-WO8-2023		
	26	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.0	0.0	34.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	█	100.0	26	GaHV-1-Egy-WO7-2023	
	27	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.0	0.0	34.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	█	27	GaHV-1-Egy-WO5-2023	
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27					

Figure 8. Amino acid identity of the sequenced *ICP4* gene compared to vaccination strains and vaccine-like strains of both CEO and TCO, as well as other Egyptian strains.

		Percent Identity																				
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18			
Divergence	1	■	100.0	100.0	100.0	100.0	100.0	100.0	99.3	99.4	100.0	100.0	99.9	99.8	99.8	99.8	99.8	100.0	100.0	1	GaHV-1-IVAX	
	2	0.0	■	100.0	100.0	100.0	100.0	100.0	99.3	99.4	100.0	100.0	99.9	99.8	99.8	99.8	99.8	99.8	100.0	100.0	2	GaHV-1-81658
	3	0.0	0.0	■	100.0	100.0	100.0	100.0	99.3	99.4	100.0	100.0	99.9	99.8	99.8	99.8	99.8	99.8	100.0	100.0	3	GaHV-1-USDA-reference
	4	0.0	0.0	0.0	■	100.0	100.0	100.0	99.3	99.4	100.0	100.0	99.9	99.8	99.8	99.8	99.8	99.8	100.0	100.0	4	GaHV-1-CEO-TRVX
	5	0.0	0.0	0.0	0.0	■	100.0	100.0	99.3	99.4	100.0	100.0	99.9	99.8	99.8	99.8	99.8	99.8	100.0	100.0	5	GaHV-1-LT-Blen
	6	0.0	0.0	0.0	0.0	0.0	■	100.0	99.3	99.4	100.0	100.0	99.9	99.8	99.8	99.8	99.8	99.8	100.0	100.0	6	GaHV-1-live-attenuated-Serva
	7	0.0	0.0	0.0	0.0	0.0	0.0	■	99.3	99.4	100.0	100.0	99.9	99.8	99.8	99.8	99.8	99.8	100.0	100.0	7	GaHV-1-ACC78
	8	0.7	0.7	0.7	0.7	0.7	0.7	0.7	■	99.9	99.3	99.3	99.2	99.1	99.1	99.1	99.1	99.1	99.3	99.3	8	GaHV-1-SA2
	9	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.1	■	99.4	99.4	99.3	99.2	99.2	99.2	99.2	99.2	99.4	99.4	9	GaHV-1-WG
	10	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.6	■	100.0	99.9	99.8	99.8	99.8	99.8	99.8	100.0	100.0	10	GaHV-1-Alexandria-2018
	11	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.6	0.0	■	99.9	99.8	99.8	99.8	99.8	99.8	100.0	100.0	11	GaHV-1-Sharkia-2018
	12	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.8	0.7	0.1	0.1	■	99.9	99.9	99.7	99.7	99.7	99.9	99.9	12	GaHV-1-Mansoura-2019
	13	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.9	0.8	0.2	0.2	0.1	■	100.0	99.8	99.8	99.8	99.8	99.8	13	GaHV-1-Fayoum-2019
	14	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.9	0.8	0.2	0.2	0.1	0.0	■	99.8	99.8	99.8	99.8	99.8	14	GaHV-1-Qalubia-2018
	15	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.9	0.8	0.2	0.2	0.3	0.2	0.2	■	100.0	99.8	99.8	99.8	15	GaHV-1-Egy-WO1-2023
	16	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.9	0.8	0.2	0.2	0.3	0.2	0.2	0.0	■	99.8	99.8	99.8	16	GaHV-1-Egy-WO4-2023
	17	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.6	0.0	0.0	0.1	0.2	0.2	0.2	0.2	■	100.0	99.8	17	GaHV-1-Egy-WO5-2023
	18	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.6	0.0	0.0	0.1	0.2	0.2	0.2	0.2	0.0	■	99.8	18	GaHV-1-Egy-WO8-2023
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18				

Figure 9. Amino Acid identity of the sequenced *gD* gene compared to vaccination strains and vaccine-like strains of both CEO and TCO, as well as other Egyptian strains.




Figure 10. Amino Acid identity of the sequenced *gG* gene compared to vaccination strains and vaccine-like strain of both CEO and TCO, as well as other Egyptian strains.




Figure 11. Amino Acid identity of the sequenced *TK* gene compared to vaccination strains and vaccine-like strains of both CEO and TCO, as well as other Egyptian strains.

DISCUSSION

The ILTV has been identified in Egypt for the first time in 1983 (Tantawi et al., 1983), and outbreaks have continued until the most recent outbreaks in layer and broiler farms in 2021 (Ali et al., 2014; Bayoumi et al., 2020; Ibrahim et

al., 2021; Mossad et al., 2022). ILTV still spreads throughout Egypt, causing outbreaks and significant losses in chicken farms (Bayoumi et al., 2020; Ibrahim et al., 2021; Mossad et al., 2022).

This study attempted to determine the detection and identification of the infectious laryngotracheitis virus that

was an outbreak in Egypt during 2023 and the genetic characterization of four antigenic and functional genes (*ICP4*, *gD*, *gG*, and *TK*).

In this study, rapid detection of ILTV-suspected layer farms from 8 governorates suffered from respiratory signs such as Dysnea, gasping, coughing, red exudates from respiratory orifices, nasal discharge, and swelling of the infraorbital sinus and moderate mortalities (5-15%) as previously detected (Hughes et al., 1991; Ali et al., 2014; Bayoumi et al., 2020). Upon post-mortem examination, the suspected chicken had hemorrhagic tracheitis with caseated material and blood clots that may have led to a blocked laryngeal lumen, as previously recorded (Preis et al., 2013; Bayoumi et al., 2020).

The symptoms and post-mortem are not sufficient to diagnose ILTV, and the diagnosis was confirmed by a rapid molecular technique (real-time-PCR) (Pang et al., 2002) due to its rapid sensitivity and reproducibility (Mackay et al., 2002). In the current study, 40 out of 50 samples (80%) were positive for ILTV by real-time PCR in eight governorates (5/8 El Sharkia, 8/10 Qalubia, 14/15 Dakahlia, 6/7 Monofia, 2/3 Gharbia, 2/2 Behira, 2/2 Domiatt, and 1/3 Alexandria), in vaccinated and unvaccinated layer farms in Egypt during 2023.

To describe the genetic development of the ILT virus strains that are presently circulating in Egypt, partial sequencing and phylogenetic analysis of four genes (*ICP4*, *gD*, *gG*, and *TK*) were used. to determine whether an outbreak in Egyptian fields was caused by a wild field strain or a circulating vaccine strain. This was in line with earlier research that showed these genes were commonly used to differentiate between field and vaccine strains and identify the strains' virulence (Shehata et al., 2013; Craig et al., 2017; Bayoumi et al., 2020).

As *ICP4* is a critical viral protein that is typically employed in epidemiologic research to classify circulating virus strains and contribute to the regulation of gene expression of the virus (Shehata et al., 2013) additionally, the *ICP4* gene's nucleotide sequence was able to differentiate between vaccine strains and field isolates (Chacón and Ferreira, 2009). The Phylogenetic tree of the *ICP4* gene was split into two categories: TCO and CEO vaccine and vaccine-like strains, as previously reported (Oldoni and García, 2007; Couto et al., 2015; Bayoumi et al., 2020).

According to sequence and phylogenetic analysis of *ICP4* gene of the strains under study, 7 out of 10 Egyptian strains were clustered in TCO group with TCO vaccine strain (IVAX used in Egypt, TCO low passage, TCO high passage) and virulent vaccine like strains from USA

(USDA, 81658) as well as Egyptian strains during 2015-2021 with 100% A.A. identity as previously described (Nagy et al., 2020; Ibrahim et al., 2021; Mossad et al., 2022). The remaining three strains in this study were grouped with the CEO vaccine strains (TRVX, live attenuated serva used in Egypt, CEO low passage, CEO high passage) and virulent vaccine like strains from Australia (ACC78), which had 98.9%-100% amino acid identity as recorded by Shehata et al. (2013), Bayoumi et al. (2020), and Mossad et al. (2022). However, this strain differed from the Egyptian strain that was recently circulated in Egypt in 2021, which had a 96.7%-97.8% A.A. identity. As a result of sequenced strains in the present study, the CEO and TCO-like virus strains were found and circulated in Egypt during 2023, causing severe outbreaks, most of which were TCO-like virus strains (70%). However, compared to TCO reverting, it has been demonstrated that chicken embryo origin reverting causes more serious respiratory illnesses and increased mortality (García, 2017).

According to earlier research by Chacón and Ferreira (2009), the CEO vaccine-like strains are identified by deletions in the 272–283 bp and V200M in the *ICP4* gene. These deletions were recorded in GAHV-1-Eg-WO5, WO7, and WO8 that cluster with CEO vaccine and vaccine like strains. Furthermore, the findings were consistent with earlier research conducted in Egypt by Nagy et al. (2020) and Mossad et al. (2022). Additionally, two novel A.A. mutations (Q161H and Q182H) unique to GAHV-1-Eg-WO8-2023 were discovered in this work. These mutations may impair the protein's structure and configuration, impacting its biological function (Sotomayor-Vivas et al., 2022). We need further research to study the impact of these mutations on the virulence of the virus.

The envelope Glycoproteins genes (G), such as *gG*, *gJ*, and *gD*, have been shown in previous studies to be crucial for the pathogenicity and antigenicity of ILTV in chickens. Additionally, field and vaccine strains can be differentiated from one another by using specific nucleotide mutations in the *gG* gene, such as 316, which serve as markers (Helferich et al., 2007; Craig et al., 2017). Additionally, Han and Kim (2001) found that the threonine at positions 67 and 103 was unique to vaccination strains. Previously, vaccination strains were distinguished from some Argentinean isolates using the nucleotide mutation at 163 in the *gD* gene (Craig et al., 2017).

According to *Gd*, *Gg* phylogenetic analysis, there is no difference in phylogenetic analysis between the CEO

group and TCO group as previously recorded (Ali et al., 2014; Bayoumi et al., 2020). The strains in this study showed 99.7%, 100%, and 100% amino acid sequence identity with the TCO vaccine strain, IVAX, and CEO vaccine strains TRVX, live attenuated serva, virulent vaccine like strains from the USA and Australis (USDA, 81658, ACC78), and Egyptian strains in 2018-2019 respectively. Additionally, there was no variation between the Egyptian and vaccine strains in the nucleotide locations at position 163 of the gD gene and 316 of the gG gene. These findings are in line with Ali et al. (2014) and Bayoumi et al. (2020), and it had threonine in the gG gene at 67 and 103 as vaccine and low virulent strain as previously detected (Ali et al., 2014). The GAHV-1-Eg-WO1 and GAHV-1-Eg-WO4 had new mutations at A34G and P276L in the gD gene that clustered them in the new branch that may affect the viral virulence (Huang et al., 1997; Bayoumi et al., 2020; Wu et al., 2022). Further studies need to determine their effectiveness on the virulence of the virus.

According to Han and Kim (2001), the *TK* gene is crucial for distinguishing between field isolates and ILTV vaccine strains and has been linked to ILTV pathogenicity and virulence. Different levels of pathogenicity have been associated with single-nucleotide polymorphisms in the *TK* gene. Furthermore, a number of *Tk* gene mutations were obtained to demonstrate viral attenuation for vaccine production. According to the current study's phylogenetically examined and sequenced *TK* gene from four isolates, there were no variations between the CEO and TCO groups. The strains showed 97.2% to 100% with CEO vaccine strain (LT Blen, TRVX, live attenuated serva, used in Egypt) and the TCO vaccine strain (IVAX, used in Egypt) along with virulent vaccine like strains from the USA, and Australia (USDA, 81658, ACC78) and Egyptian strains. According to the mutational investigation of the *Tk* gene, the GAHV-1-Eg-WO5 had A99E and GAHV-1-Eg-WO8 had R115I, G126A, and S163I that may have an impact on the virus pathogenicity (Han and Kim 2001; Santander-Parra et al., 2022). More research will be required to ascertain the efficacy of the pathogenicity of the virus.

The molecular characterization and phylogenetic findings of four genes (*ICP4*, *gD*, *gG*, and *Tk*) in strains isolated during 2023 indicated that outbreaks in Egyptian commercial broiler chicken flocks were related to ILTV vaccine strains. These findings align with other research on ILTV in Egyptian layer farms (Shehata et al., 2013; Ali et al., 2014; Bayoumi et al., 2020), which postulated that the CEO and TCO vaccination viruses would become

more virulent following bird-to-bird transmissions, resulting in devastating epidemics among Egypt's susceptible chickens. Alternatively, the attenuated vaccine might have reactivated and caused outbreaks in susceptible chickens as a result of chicken-to-chicken transmission or the reactivation of latent infection brought on by stress, poor hygiene, and the spread of other pathogens. These results align with those obtained by Oldoni and García (2007), who demonstrated that the vaccination strains were closely linked to most commercial chicken ILTV isolates. According to Chang et al. (1997), outbreaks of ILTV occur when ILTV vaccine viruses take the place of naturally occurring viruses circulating in the field. Additionally, it may be recombination that occurred between several attenuated vaccination strains, resulting in virulent recombinant viruses, which became the dominant strains in commercial poultry flocks as recorded by Lee et al. (2012). We recommend performing a full genome sequence of ILTV to detect any recombination occurrence.

CONCLUSION

According to molecular characterization of *ICP4*, *gG*, *Gd*, and *TK* genes, the ILTV outbreaks in poultry farms across several regions of Egypt during 2023 might be induced by vaccine strains derived from TCO and CEO, with some acquired mutations that may affect the virulence of the virus. It could be caused by reactivation of a viral vaccine strain from chicken to chicken transmission or revival of latent infection, or viral recombination of modified attenuated vaccines. Therefore, to stop ILTV outbreaks in the future, there is a need to reevaluate current vaccination programs and use novel vector vaccines.

DECLARATIONS

Authors' contributions

Sabry Omar contributed to collecting samples. Ahmed Abdelhalim and Zienab Mossad performed PCR for *TK*, *gG*, *gD*, and *ICP4*. Nahed Yehia and Wessam Hassan made the sequence and phylogenetic analyses. Nahed Yehia and Wessam Hassan wrote the manuscript draft and revised it before submission. All authors checked and confirmed all data and the last draft of the manuscript before submission to the journal.

Acknowledgements

The authors would like to thank the Reference Laboratory for Quality Control on Poultry Production

(RLQP) and the Animal Health Research Institute for providing facilities and supporting this study.

Funding

This study was funded by the Reference Laboratory for Quality Control in Poultry Production (RLQP), Animal Health Research Institute.

Ethical considerations

The final version of this study has been reviewed by all authors and submitted for the first time to this publication.

Availability of data and materials

The study's original contributions are contained in the article and supplemental materials. Data is available upon reasonable request from the corresponding author.

Competing interests

The authors declare no conflict of interests.

REFERENCES

- Ali AMA, Mansour SMG, Mohamed MHA, Ali H, and Shahin A (2014). Molecular characterization of thymidine kinase and glycoprotein G genes from a possible vaccine induced infectious laryngotracheitis outbreak in Egypt. *Pakistan Veterinary Journal*, 34(3): 381-385. Available at: <https://sqa.elsevierpure.com/en/publications/molecular-characterization-of-thymidine-kinase-and-glycoprotein-g>
- Abebe S, Ferrara G, Getachew B, Hirpa E, and Moje N (2024). Serological and Molecular Investigation of Infectious Laryngotracheitis Virus in Chickens from Robe Town, Southeastern Ethiopia. *Animals*, 14(22): 3227. DOI: <https://www.doi.org/10.3390/ani14223227>
- Asif K, O'Rourke D, Shil P, Steer-Cope PA, Legione AR, Marenda MS, and Noormohammadi AH (2022). Rapid typing of infectious laryngotracheitis virus directly from tracheal tissues based on next-generation sequencing. *Archives of Virology*, 167(4): 1151-1155. DOI: <https://www.doi.org/10.1007/s00705-022-05393-y>
- Bagust, Jones R, and Guy J (2000). Avian infectious laryngotracheitis Aetiological agent. *Revue Scientifique et Technique*, 19(2): 483-492. Available at: <https://europepmc.org/article/med/10935275>
- Bagust GTJ (2003). Laryngotracheitis. In: Y. M. Saif, H. J. Barnes, J. R. Glisson, A. M. Fadley, L. R. McDougald, and D. E. Swayne (Editors), *Diseases of poultry*, pp. 121-134. DOI: [https://www.doi.org/10.1647/1082-6742\(2003\)017\[0109:BR\]2.0.CO;2](https://www.doi.org/10.1647/1082-6742(2003)017[0109:BR]2.0.CO;2)
- Bayoumi M, El-Saied M, Amer H, Bastami M, Sakr EE, and El-Mahdy M (2020). Molecular characterization and genetic diversity of the infectious laryngotracheitis virus strains circulating in Egypt during the outbreaks of 2018 and 2019. *Archives of Virology*, 165(3): 661-670. Available at: <https://link.springer.com/article/10.1007/s00705-019-04522-4>
- Blacker HP, Kirkpatrick NC, Rubite A, Rourke D O', and Noormohammadi AH (2011). Epidemiology of recent outbreaks of infectious laryngotracheitis in poultry in Australia. *Australian Veterinary Journal*, 89(3): 89-94. DOI: <https://www.doi.org/10.1111/j.1751-0813.2010.00665.x>
- Burland TG (2000). DNASTAR's lasergene sequence analysis software. *Methods in Molecular Biology*, 132: 71-91. DOI: <https://www.doi.org/10.1385/1-59259-192-2:71>
- Chacón JL and Ferreira AJ (2009). Differentiation of field isolates and vaccine strains of infectious laryngotracheitis virus by DNA sequencing. *Vaccine*, 27(48): 6731-6738. DOI: <https://www.doi.org/10.1016/j.vaccine.2009.08.083>
- Chang PC, Lee YL, Shien JH, and Shieh HK (1997). Rapid differentiation of vaccine strains and field isolates of infectious laryngotracheitis virus by restriction fragment length polymorphism of PCR products. *Journal of Virological Methods*, 66(2): 179-86. DOI: [https://www.doi.org/10.1016/S0166-0934\(97\)00050-5](https://www.doi.org/10.1016/S0166-0934(97)00050-5)
- Coppo MJ, Noormohammadi AH, Browning GF, and Devlin JM (2013). Challenges and recent advancements in infectious laryngotracheitis virus vaccines. *Avian Pathology*, 42(3): 195-205. DOI: <https://www.doi.org/10.1080/03079457.2013.800634>
- Couto Rde M, Preis IS, Braga JF, Brasil BS, Drummond MG, Martins NR, and Ecco R (2015). Molecular characterization of infectious laryngotracheitis virus in naturally infected egg layer chickens in a multi-age flock in Brazil. *Archives of Virology*, 160(1): 241-252. DOI: <https://www.doi.org/10.1007/s00705-014-2273-2>
- Craig MI, Rojas MF, van der Ploeg CA, Olivera V, Vagnozzi AE, Perez AM, and König GA (2017). Molecular characterization and cluster analysis of field isolates of avian infectious laryngotracheitis virus from Argentina. *Frontier of Veterinary Science*, 4: 212. DOI: <https://www.doi.org/10.3389/fvets.2017.00212>
- Creelan JL, Calvert VM, Graham DA, and McCullough SJ (2006). Rapid detection and characterization from field cases of infectious laryngotracheitis virus by real-time polymerase chain reaction and restriction fragment length polymorphism. *Avian Pathology*, 35(2): 173-179. DOI: <https://www.doi.org/10.1080/03079450600598244>
- Davidson I, Raibstein I, and Altory A (2015). Differential diagnosis of fowlpox and infectious laryngotracheitis viruses in chicken diphtheritic manifestations by mono and duplex real-time polymerase chain reaction. *Avian Pathology*, 44(1): 1-4. DOI: <https://www.doi.org/10.1080/03079457.2014.977223>
- Devlin JM, Browning GF, Hartley CA, Kirkpatrick NC, Mahmoudian A, Noormohammadi AH, and Gilkerson JR (2006). Glycoprotein G is a virulence factor in infectious laryngotracheitis virus. *Journal of General Virology*, 87(10): 2839-2847. DOI: <https://www.doi.org/10.1099/vir.0.82194-0>
- Di Giovine P, Settembre EC, Bhargava AK, Luftig MA, Lou H, Cohen GH, Eisenberg RJ, Krummenacher C, and Carfi A (2011). Structure of herpes simplex virus glycoprotein D bound to the human receptor nectin-1. *PLoS Pathogen*, 7(9): e1002277. DOI: <https://www.doi.org/10.1371/journal.ppat.1002277>
- Elshafie EA, Isham IM, Najimudeen SM, Perez-Contreras A, Barboza-Solis C, Ravi M, and Abdul-Careem MF (2022). Host responses following infection with canadian-origin wildtype and vaccine revertant infectious Laryngotracheitis virus. *Vaccines*, 10(5): 782. DOI: <https://www.doi.org/10.3390/vaccines10050782>
- García M (2017). Current and future vaccines and vaccination strategies against infectious laryngotracheitis (ILT) respiratory disease of poultry. *Veterinary Microbiology*, 206: 157-162. DOI: <https://www.doi.org/10.1016/j.vetmic.2016.12.023>
- Groves PJ, Williamson SL, Sharpe SM, Gerber PF, Gao YK, Hirn TJ, and Walkden-Brown SW (2019). Uptake and spread of infectious laryngotracheitis vaccine virus within meat chicken flocks following drinking water vaccination. *Vaccine*, 37(35): 5035-5043. DOI: <https://www.doi.org/10.1016/j.vaccine.2019.06.087>
- Han MG and Kim SJ (2001). Analysis of Korean strains of infectious laryngotracheitis virus by nucleotide sequences and restriction fragment length polymorphism. *Veterinary of Microbiology*, 83(4): 321-331. DOI: [https://www.doi.org/10.1016/S0378-1135\(01\)00423-0](https://www.doi.org/10.1016/S0378-1135(01)00423-0)

- Helferich D, Veits J, Teifke JP, Mettenleiter TC, and Fuchs W (2007). The UL47 gene of avian infectious laryngotracheitis virus is not essential for *in vitro* replication but is relevant for virulence in chickens. *Journal of General Virology*, 88: 732-742. DOI: <https://www.doi.org/10.1099/vir.0.82533-0>
- Hermann S, Stevens MJA, Sigrist B, Bilic I, Albini S, and Wolfrum N (2024). Unveiling the genetic landscape of infectious laryngotracheitis virus in Switzerland: Evidence for vaccine-like and wild-type strains. *Virology*, 600: 110217. DOI: <https://www.doi.org/10.1016/j.virol.2024.110217>
- Hong X, Zhang H, Zhang X, Zhang XP, and Zhang T (2024). A meta-analysis for prevalence of infectious laryngotracheitis in chickens in mainland China in 1981-2022. *BMC Veterinary Research*, 20(1): 142. DOI: <https://www.doi.org/10.1186/s12917-024-03991-3>
- Huang Q, Mat-Arip Y, and Guo P (1997). Sequencing of a 5.5-kb DNA fragment and identification of a gene coding for a subunit of the helicase/primase complex of avian laryngotracheitis virus (ILTV). *Virus Genes*, 15(2): 119-21. DOI: <https://www.doi.org/10.1023/A:1007958807339>
- Hughes CS, Williams RA, Gaskell RM, Jordan FT, Bradbury JM, Bennett M, and Jones RC (1991). Latency and reactivation of infectious laryngotracheitis vaccine virus. *Achieve of Virology*, 121(1-4): 213-218. DOI: <https://www.doi.org/10.1007/BF01316755>
- Ibrahim SF, Zayan KA, and Saad AE (2021). Molecular characterization and isolation of Infectious laryngotracheitis virus (ILTV) strains causing outbreaks in layer chicken farms of Qalyubia Province, Egypt. *Benha Veterinary Medical Journal*, 40: 126-130. DOI: <https://www.doi.org/10.21608/bvmj.2021.71229.1391>
- Kardoğan Ö and Sarıçam İnce S (2024). Molecular characterization and phylogenetic analysis of infectious laryngotracheitis virus isolates from commercial chicken flocks in Turkey. *Archives of Virology*, 169(11): 231. DOI: <https://www.doi.org/10.3390/v17020213>
- Kirkpatrick NC, Mahmoudian A, O'Rourke D, and Noormohammadi AH (2006). Differentiation of infectious laryngotracheitis virus isolates by restriction fragment length polymorphic analysis of polymerase chain reaction products amplified from multiple genes. *Avian Disease*, 50(1): 28-34. DOI: <https://www.doi.org/10.1637/7414-072205R.1>
- Kumar S, Stecher G, and Tamura K (2016). MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets. *Molecular Biology Evolution*, 33(7): 1870-1874. DOI: <https://www.doi.org/10.1093/molbev/msw054>
- Lazear E, Whitbeck JC, Ponce-de-Leon M, Cairns TM, Willis SH, Zuo Y, Krummenacher C, Cohen GH, and Eisenberg RJ (2012). Antibody-induced conformational changes in herpes simplex virus glycoprotein gD reveal new targets for virus neutralization. *Journal of Virology*, 86(3): 1563-1576. DOI: <https://www.doi.org/10.1128/JVI.06480-11>
- Lee SW, Markham PF, Markham JF, Petermann I, Noormohammadi AH, Browning GF, Ficorilli NP, Hartley CA, and Devlin JM (2011). First complete genome sequence of infectious laryngotracheitis virus. *BMC Genomics*, 12: 197. DOI: <https://www.doi.org/10.1186/1471-2164-12-197>
- Lee J (2011). Host-virus interactions of infectious laryngotracheitis virus infection in cultured cells. Graduate Theses and Dissertations, University of Arkansas, Fayetteville, United States. Available at: <https://scholarworks.uark.edu/etd/183>
- Lee SW, Markham PF, Coppo MJ, Legione AR, Markham JF, Noormohammadi AH, Browning GF, Ficorilli N, Hartley CA, and Devlin JM (2012). Attenuated vaccines can recombine to form virulent field viruses. *Science*, 337(6091): 188. DOI: <https://www.doi.org/10.1126/science.1217134>
- Mackay IM, Arden KE, and Nitsche A (2002). Real-time PCR in virology. *Nucleic Acids Research*, 30(6): 1292-1305. DOI: <https://www.doi.org/10.1093/nar/30.6.1292>
- Magouz A, Medhat S, Abou Asa S, and Desouky A (2018). Detection of infectious laryngotracheitis virus (*Gallid herpesvirus-1*) from clinically infected chickens in Egypt by different diagnostic methods. *Iran Journal of Veterinary Research*, 19(3): 194. Available at: <https://pmc.ncbi.nlm.nih.gov/articles/PMC6184029/>
- Menendez KR, García M, Spatz S, and Tablante NL (2014). Molecular epidemiology of infectious laryngotracheitis: A review. *Avian Pathology*, 43: 108-117. DOI: <https://www.doi.org/10.1080/03079457.2014.886004>
- Mossad Z, Moussa SA, Saied M, Fathy MM, and Zanaty AM (2022). Molecular and genetic detection of infectious laryngotracheitis disease virus in broiler farms after a disease outbreak in Egypt. *Virus Disease*, 33(4): 404-412. DOI: <https://www.doi.org/10.1007/s13337-022-00792-w>
- Nagy N, Sherif MI, Radwan A, Sayed R, El-Moneim A, Fathy N, and El-Zahed H (2020). Isolation and molecular characterization of circulating infectious laryngotracheitis (ILT) virus in Egypt, 2018. *Journal of the Egyptian Medical Association*, 79(3): 743-759. Available at: https://journals.ekb.eg/article_306200.html
- Ojkic D, Swinton J, Vallieres M, Martin E, Shapiro J, Sanei B, and Binnington B (2006). Characterization of field isolates of infectious laryngotracheitis virus from Ontario. *Avian Pathology*, 35(4): 286-292. DOI: <https://www.doi.org/10.1080/03079450600815481>
- Oldoni I and García M (2007). Characterization of infectious laryngotracheitis virus isolates from the US by polymerase chain reaction and restriction fragment length polymorphism of multiple genome regions. *Avian Pathology*, 36(2): 167-176. DOI: <https://www.doi.org/10.1080/03079450701216654>
- Pang Y, Wang H, Girshick T, Xie Z, and Khan MI (2002). Development and application of a multiplex polymerase chain reaction for avian respiratory agents. *Avian Disease*, 46(3): 691-699. DOI: [https://www.doi.org/10.1637/0005-2086\(2002\)046\[0691:DAAOAM\]2.0.CO;2](https://www.doi.org/10.1637/0005-2086(2002)046[0691:DAAOAM]2.0.CO;2)
- Ponnusamy P, Sukumar K, Raja A, Saravanan S, Srinivasan P, and Thangavelu A (2022). Characterization of infectious laryngotracheitis virus isolates from laying hens during 2019-2020 outbreaks in Tamil Nadu, India. *Archives of Virology*, 167(9): 1819-1829. DOI: <https://www.doi.org/10.1007/s00705-022-05485-9>
- Preis IS, Braga JF, Couto RM, Brasil BS, Martins NR, and Ecco R (2013). Outbreak of infectious laryngotracheitis in large multi-age egg layer chicken flocks in Minas Gerais, Brazil. *Pesquisa Veterinária Brasileira*, 33(5): 591-596. DOI: <https://www.doi.org/10.1590/S0100-736X2013000500007>
- Rouse BT and Kaistha SD (2006). A tale of 2 alpha-herpesviruses: lessons for vaccinologists. *Clinical Infectious Diseases*, 42(6): 810-817. DOI: <https://www.doi.org/10.1086/500141>
- Santander Parra S, Nunez L, Buim MR, Astolfi-Ferreira CS, and Piantino Ferreira AJ (2018). Development of a qPCR for the detection of infectious laryngotracheitis virus (ILTV) based on the gE gene. *British Poultry Science*, 59(4): 402-407. DOI: <https://www.doi.org/10.1080/00071668.2018.1479060>
- Santander-Parra SH, Nuñez LFN, Buim MR, Ferreira CSA, Loncoman CA, and Ferreira AJP (2022). Detection and molecular characterization of infectious laryngotracheitis virus (ILTV) in chicken with respiratory signs in Brazil during 2015 and 2016. *Brazil Journal of Microbiology*, 53(4): 2223-2232. DOI: <https://www.doi.org/10.1007/s42770-022-00833-y>
- Shao G, Fu J, Pan Y., Gong S, Song C, Chen S, Feng, K, Zhang X, and Xie Q (2025). Development of a recombinant infectious bronchitis virus vaccine expressing infectious laryngotracheitis virus multiple epitopes. *Poultry Science*, 104(1): 104578. DOI: <https://www.doi.org/10.1016/j.psj.2024.104578>
- Shehata AA, Halami MY, Sultan HH, Abd El-Razik AG, and Vahlenkamp TW (2013). Chicken embryo origin-like strains are responsible for Infectious laryngotracheitis virus outbreaks in

- Egyptian cross-bred broiler chickens. *Virus Genes*, 46(3): 423-430. DOI: <https://www.doi.org/10.1007/s11262-012-0870-2>
- Sotomayor-Vivas C, Hernández-Lemus E, and Dorantes-Gilardi R (2022). Linking protein structural and functional change to mutation using amino acid networks. *PLoS One*. 17(1): e0261829. DOI: <https://www.doi.org/10.1371/journal.pone.0261829>
- Tamura K, Stecher G, Peterson D, Filipski A, and Kumar S (2013). MEGA6: Molecular evolutionary genetics analysis, version 6.0. *Molecular Biology and Evolution*, 30(12): 2725-2729. DOI: <https://www.doi.org/10.1093/molbev/mst197>
- Tantawi HH, El Batrawi AM, Bastami MA, Youssef YI, and Fawzia MM (1983). Avian infectious laryngo-tracheitis in Egypt. I. Epidemiology, virus isolation and identification. *Veterinary Research Community*, 6(4): 281-287. DOI: <https://www.doi.org/10.1007/BF02214923>
- Wang Z, Qiao Y, Chen Z, Liang Y, Cui L, Zhang Y, Li X, Xu L, Wei P, Liu S et al. (2021). Fos facilitates gallid alpha-herpesvirus 1 infection by transcriptional control of host metabolic genes and viral immediate early gene. *Viruses*, 13(6): 1110. DOI: <https://www.doi.org/10.3390/v13061110>
- Wolfrum N (2020). Infectious laryngotracheitis: An update on current approaches for prevention of an old disease. *Journal of Animal Science*, 98: 27-35. DOI: <https://www.doi.org/10.1093/jas/skaa133>
- Wu M, Zhang Z, Su X, Lu H, Li X, Yuan C, Liu Q, Teng Q, Geri L, and Li Z (2022). Biological characteristics of infectious laryngotracheitis viruses isolated in China. *Viruses*, 14(6): 1200. DOI: <https://www.doi.org/10.3390/v14061200>
- Yi C, Li G, Mu Y, Cui S, Zhang D, Xu Q, Liang C, Wang M, Zhou S, Zhou H et al. (2024). Isolation, identification, molecular and pathogenicity characteristics of an infectious laryngotracheitis virus from Hubei province, China. *Poultry Science*, 103(2): 103271. DOI: <https://www.doi.org/10.1016/j.psj.2023.103271>
- Zhao Y, Kong C, Cui X, Cui H, Shi X, Zhang X, Hu S, Hao L, and Wang Y (2013). Detection of infectious laryngotracheitis virus by real-time PCR in naturally and experimentally infected chickens. *PLoS One*, 28(6): e67598. DOI: <https://www.doi.org/10.1371/journal.pone.0067598>

Publisher's note: [Scienceline Publication](#) Ltd. remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <https://creativecommons.org/licenses/by/4.0/>.